Central Garden & Pet Revises Outlook for Fiscal 2022 GAAP EPS
Fiscal 2022 GAAP EPS now expected to be at or above prior year Lower outlook…
Fiscal 2022 GAAP EPS now expected to be at or above prior year Lower outlook…
Speedcast’s network integrates Comtech VSAT technology to increase the speed and resilience of electronic point-of-sale…
Tel Aviv, June 21, 2022 – RevealSecurity, the leader of Application Detection and Response, is…
Sumsub, a global identity verification software provider, offers Compliance-as-a-Service for regulated businesses to help them…
The Company’s improved, new Vitastem products have recently begun large scale production LOS ANGELES, June…
SAN DIEGO, June 22, 2022 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech…
Lonza and Edinburgh Genome Foundry to present their high-throughput single-cell screening workflow use cases using…
Image 1 Whitney Johns ACTIVE LAS VEGAS, June 22, 2022 (GLOBE NEWSWIRE) — Healthy Extracts…
VANCOUVER, Washington, June 22, 2022 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the…
Company to discuss positive topline and additional clinical data for CY6463 in MELAS patients Mitochondrial…
BMF-219, a covalent menin inhibitor, is the first menin inhibitor administered to patients with relapsed/refractory…
Company executes on strategy to extend cash runway by monetizing non-core assets Total transaction value…
BOSTON, June 22, 2022 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical…
SOUTH SAN FRANCISCO, Calif., June 22, 2022 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB), a…
BOSTON, June 22, 2022 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical…
BELTSVILLE, Md., June 22, 2022 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company…
Results were published in the European Journal of Clinical Microbiology & Infectious Diseases Serial specimen…
Prevention of Type 1 Diabetes in a Stringent Preclinical Model from Ongoing Experiment;Two Antigens Prevent…
Highlights: 10 subjects in cohort six intravenously dosed with RECCE® 327 at 4,000mg demonstrated good…
Multicenter Phase 1/2 clinical trial evaluating the safety and efficacy of MB-106 for relapsed or…